Roche’s Smart-Bomb Cancer Drug Delays Breast-Tumor Growth
This article is for subscribers only.
An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.
The treatment, combining Roche’s Herceptin with an older chemotherapy medicine, delayed progression of tumors 3.2 months longer than GlaxoSmithKline Plc’s Tykerb with chemotherapy in women with advanced disease. The data is being reported today at the American Society of Clinical Oncology meeting in Chicago.